Literature DB >> 15630572

Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging.

A Hansch1, R Rzanny, J-P Heyne, U Leder, J R Reichenbach, W A Kaiser.   

Abstract

Dilated cardiomyopathy (DCM) is accompanied by an impaired cardiac energy metabolism. The aim of this study was to investigate metabolic ratios in patients with DCM compared to controls by using spectroscopic two-dimensional chemical shift imaging (2D-CSI). Twenty volunteers and 15 patients with severe symptoms (left ventricular ejection fraction, LVEF<30%) and ten patients with moderate symptoms (LVEF>30%) of DCM were investigated. Cardiac 31P MR 2D-CSI measurements (voxel size: 40x40x100 mm3) were performed with a 1.5 T whole-body scanner. Measurement time ranged from 15 min to 30 min. Peak areas and ratios of different metabolites were evaluated, including high-energy phosphates (PCr, ATP), 2,3-diphosphoglycerate (2,3-DPG) and phosphodiesters (PDE). In addition, we evaluated how PCr/ATP ratios correlate with LVEF as an established prognostic factor of heart failure. The PCr/gamma-ATP ratio was significantly decreased in patients with moderate and severe DCM and showed a linear correlation with reduced LVEFs. PDE/ATP ratios were significantly increased only in patients with severe DCM as compared to volunteers. Applying 31P MRS with commonly-available 2D-CSI sequences is a valuable technique to evaluate DCM by determining PCr/ATP ratios noninvasively. In addition to reduced PCr/ATP ratios observed in patients suffering from DCM, significantly-increased PDE/ATP ratios were found in patients with severe DCM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630572     DOI: 10.1007/s00330-004-2504-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

Review 1.  Mitochondria and apoptosis.

Authors:  D R Green; J C Reed
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

2.  Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart.

Authors:  S Schaefer; J Gober; M Valenza; G S Karczmar; G B Matson; S A Camacho; E H Botvinick; B Massie; M W Weiner
Journal:  J Am Coll Cardiol       Date:  1988-12       Impact factor: 24.094

Review 3.  Magnetic resonance spectroscopy of the heart.

Authors:  S Schaefer; B Massie; M W Weiner
Journal:  Cardiol Clin       Date:  1989-08       Impact factor: 2.213

4.  Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy.

Authors:  M Meininger; W Landschütz; M Beer; T Seyfarth; M Horn; T Pabst; A Haase; D Hahn; S Neubauer; M von Kienlin
Journal:  Magn Reson Med       Date:  1999-04       Impact factor: 4.668

5.  In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease.

Authors:  S Schaefer; J R Gober; G G Schwartz; D B Twieg; M W Weiner; B Massie
Journal:  Am J Cardiol       Date:  1990-05-01       Impact factor: 2.778

6.  High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies--the study using ECG gated MR spectroscopy with a localization technique.

Authors:  Y Masuda; Y Tateno; H Ikehira; T Hashimoto; F Shishido; M Sekiya; Y Imazeki; H Imai; S Watanabe; Y Inagaki
Journal:  Jpn Circ J       Date:  1992-06

7.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

8.  31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.

Authors:  S Neubauer; T Krahe; R Schindler; M Horn; H Hillenbrand; C Entzeroth; H Mader; E P Kromer; G A Riegger; K Lackner
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

9.  [The direct measurement of the spin-grid-relaxation times of phosphorus metabolites in the human myocardium].

Authors:  R Schindler; T Krahe; S Neubauer; H Hillenbrand; C Entzeroth; M Horn; K Lackner; G Ertl
Journal:  Rofo       Date:  1992-11

Review 10.  Molecular mechanisms of inherited cardiomyopathies.

Authors:  Diane Fatkin; Robert M Graham
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

View more
  6 in total

1.  1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes.

Authors:  Francesco Secchi; Giovanni Di Leo; Marcello Petrini; Riccardo Spairani; Marco Alì; Marco Guazzi; Francesco Sardanelli
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

Review 2.  PET imaging of cardiac hypoxia: opportunities and challenges.

Authors:  M G Handley; R A Medina; E Nagel; P J Blower; R Southworth
Journal:  J Mol Cell Cardiol       Date:  2011-07-14       Impact factor: 5.000

3.  31P-MR spectroscopic imaging in hypertensive heart disease.

Authors:  J-P Heyne; R Rzanny; A Hansch; U Leder; J R Reichenbach; W A Kaiser
Journal:  Eur Radiol       Date:  2006-03-02       Impact factor: 5.315

4.  Exercise-induced modulation of cardiac lipid content in healthy lean young men.

Authors:  L Bilet; T van de Weijer; M K C Hesselink; J F C Glatz; H J Lamb; J Wildberger; M E Kooi; P Schrauwen; V B Schrauwen-Hinderling
Journal:  Basic Res Cardiol       Date:  2010-12-23       Impact factor: 17.165

5.  Cardiac energetics in patients with chronic heart failure and iron deficiency: an in-vivo 31 P magnetic resonance spectroscopy study.

Authors:  Francesco Papalia; Fadi Jouhra; George Amin-Youssef; Ajay M Shah; Geoffrey Charles-Edwards; Darlington O Okonko
Journal:  Eur J Heart Fail       Date:  2022-03-08       Impact factor: 17.349

Review 6.  Creatine deficiency and heart failure.

Authors:  Annamaria Del Franco; Giuseppe Ambrosio; Laura Baroncelli; Tommaso Pizzorusso; Andrea Barison; Iacopo Olivotto; Fabio A Recchia; Carlo M Lombardi; Marco Metra; Yu F Ferrari Chen; Claudio Passino; Michele Emdin; Giuseppe Vergaro
Journal:  Heart Fail Rev       Date:  2021-10-07       Impact factor: 4.654

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.